BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Provenge sipuleucel-T regulatory update

Dendreon said CMS will now reimburse for infusion costs associated with prostate cancer therapy Provenge sipuleucel-T. Dendreon said the standard reimbursement for infusion-based biologics is $125 per infusion....

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >